Clostridium Difficile Infection Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Name: Clostridium Difficile Infection Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
Creator: www.imarcgroup.com
Published: 2024-01-01 00:00:00
License: 暂无描述

www.imarcgroup.com2024-01-01 更新2025-03-25 收录

下载链接：

https://www.imarcgroup.com/clostridium-difficile-infection-market

下载链接

链接失效反馈

官方服务：

资源简介：

<h4><strong>Market Overview:</strong></h4> <blockquote> <p><em>The 7 major </em>Clostridium difficile infection<em> markets reached a value of US$ 9.0 Billion in </em>2023<em>. Looking forward, IMARC Group expects the 7MM to reach US$ 14.9<strong> </strong>Billion by<strong> </strong></em>2034<em>, exhibiting a growth rate (CAGR) of 4.7% during </em>2024-2034.</p> </blockquote> <table align="center" border="1" cellpadding="1" cellspacing="1" dir="ltr" style="width:100%"> <thead> <tr> <th scope="col" style="width:70%"> <div style="text-align:left">Report Attribute</div> </th> <th scope="col"> <div style="text-align:left">Key Statistics</div> </th> </tr> </thead> <tbody> <tr> <td><strong>Base Year </strong></td> <td> <div>2023</div> </td> </tr> <tr> <td><strong>Forecast Years </strong></td> <td>2024-2034</td> </tr> <tr> <td><strong>Historical Years </strong></td> <td> <div>2018-2023</div> </td> </tr> <tr> <td> <div><strong>Market Size in 2023</strong></div> </td> <td>US$ 9.0 Billion</td> </tr> <tr> <td> <div><strong>Market Forecast in 2034</strong></div> </td> <td>US$ 14.9 Billion</td> </tr> <tr> <td> <div><strong>Market Growth Rate 2024-2034</strong></div> </td> <td>4.7%</td> </tr> </tbody> </table> <p style="text-align:justify"><br /> The Clostridium difficile infection market has been comprehensively analyzed in IMARC's new report titled <strong>"Clostridium Difficile Infection Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034".</strong> Clostridium difficile infection (CDI) refers to a bacterial infection caused by the pathogenic bacterium Clostridium difficile, commonly known as C. difficile. This bacterium can colonize the colon and disrupt the normal balance of gut flora, leading to a range of gastrointestinal symptoms. The indications of CDI can vary in severity and may include watery diarrhea, abdominal pain, fever, loss of appetite, and nausea. In severe cases, the ailment can progress to pseudomembranous colitis, a more severe inflammation of the colon, which can result in life-threatening complications. Diagnosing CDI typically involves several steps. The primary method is to test a stool sample for the presence of C. difficile toxins or the bacterium itself. A positive test result, along with clinical symptoms, is often sufficient to confirm the infection. Additionally, healthcare providers may perform a colonoscopy or sigmoidoscopy to visually inspect the colon for signs of inflammation or pseudomembranes.</p> <p style="text-align:center"><img alt="Clostridium Difficile Infection Market" src="https://www.imarcgroup.com/CKEditor/80918a30-8b27-4ba5-bc3a-e8b643ffdee8clostridium-difficile-infection-market.webp" style="height:450px; width:800px" /></p> <p style="text-align:justify">The increasing utilization of broad-spectrum antibiotics, which can impair the balance of beneficial bacteria in the colon, thereby allowing C. difficile to overgrow and produce toxins that cause infection, is primarily driving the Clostridium difficile infection market. In addition to this, the inflating demand for effective medications, including vancomycin and fidaxomicin, as well as the emerging use of fecal microbiota transplantation (FMT) to restore a healthy gut microbiome, is also creating a positive outlook for the market. Moreover, the widespread adoption of infection control measures and stringent hygiene protocols in healthcare facilities, as they play a vital role in preventing CDI transmission, is further bolstering the market growth. Apart from this, the rising application of rapid diagnostic tests, such as enzyme immunoassays (EIAs) and nucleic acid amplification tests (NAATs), for early and accurate detection of the ailment is acting as another significant growth-inducing factor. Additionally, the emerging popularity of innovative treatment modalities like monoclonal antibodies targeting bacterial toxins, which aid in neutralizing the harmful effects of the bacterium, is also augmenting the market growth. Furthermore, the ongoing research into novel vaccines against C. difficile, aimed at preventing CDI occurrence in high-risk populations is expected to drive the Clostridium difficile infection market during the forecast period.</p> <p style="text-align:justify">IMARC Group's new report provides an exhaustive analysis of the Clostridium difficile infection market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Clostridium difficile infection and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Clostridium difficile infection market in any manner.</p> <h4 style="text-align:justify"><strong>Recent Developments:</strong></h4> <ul> <li style="text-align:justify">In May 2024, Vedanta Biosciences reported that the first patient had been dosed in the global Phase 3 RESTORATiVE303 clinical trial. The RESTORATiVE303 trial is assessing the efficacy and safety of VE303 in patients with recurrent C. difficile infection. It is intended to serve as the foundation for a Biologics License Application (BLA) to be filed with the US Food and Drug Administration.</li> </ul> <h4 style="text-align:justify"><br /> <strong>Key Highlights:</strong></h4> <ul> <li style="text-align:justify">Clostridium difficile causes 15-25% of antibiotic-associated diarrhea and almost all cases of antibiotic-associated pseudomembranous colitis.</li> <li style="text-align:justify">More than 90% of C. difficile infections develop after or during antibiotic treatment.</li> <li style="text-align:justify">Asymptomatic carriers of C. difficile can contaminate the hospital environment. The frequency of carriers is roughly 3% in healthy persons, 20-30% in hospitalized patients, and 50% in those with lengthy hospital stays.</li> <li style="text-align:justify">The CDC estimates that C. difficile causes almost half a million illnesses in the United States each year.</li> <li style="text-align:justify">One out of every eleven patients over the age of 65 who are diagnosed with a healthcare-associated C. diff infection dies within a month.</li> </ul> <h4 style="text-align:justify"><br /> <strong>Drugs:</strong></h4> <p style="text-align:justify">ZINPLAVA is a human monoclonal antibody that binds to Clostridioides difficile toxin B. It is used to reduce the recurrence of Clostridioides difficile infection (CDI) in adults and pediatric patients aged 1 year and older who are receiving antibacterial drug treatment for CDI and are at high risk for recurrence.</p> <p style="text-align:justify">VE303 is a potential first-in-class live biotherapeutic product (LBP) candidate composed of specified bacterial consortia intended to prevent recurrent Clostridioides difficile infection. It comprises of eight strains that were rationally chosen utilizing Vedanta's product engine. VE303 is made from pure, clonal bacterial cell banks, resulting in a uniform medicinal product in powdered form and eliminating the need to rely on donor feces of varying composition.</p> <p style="text-align:justify">CP101 is an investigational microbiome treatment that delivers a whole microbial community in a single oral delivery, eliminating the requirement for bowel preparation. CP101 is intended to prevent recurrent C. difficile infection by restoring a varied microbial community and important physiological mechanisms that are thought to contribute to colonization resistance.</p> <p><br /> <strong>Time Period of the Study</strong></p> <ul> <li>Base Year: 2023</li> <li>Historical Period: 2018-2023</li> <li>Market Forecast: 2024-2034<br />  </li> </ul> <p><strong><strong>Countries Covered</strong></strong></p> <ul> <li>United States</li> <li>Germany</li> <li>France</li> <li>United Kingdom</li> <li>Italy</li> <li>Spain</li> <li>Japan<br />  </li> </ul> <p><strong>Analysis Covered Across Each Country</strong></p> <ul> <li>Historical, current, and future epidemiology scenario</li> <li>Historical, current, and future performance of the Clostridium difficile infection market</li> <li>Historical, current, and future performance of various therapeutic categories in the market</li> <li>Sales of various drugs across the Clostridium difficile infection market</li> <li>Reimbursement scenario in the market</li> <li>In-market and pipeline drugs</li> </ul> <h4><br /> <strong>Competitive Landscape:</strong></h4> <p>This report also provides a detailed analysis of the current Clostridium difficile infection marketed drugs and late-stage pipeline drugs.</p> <p><strong>In-Market Drugs</strong></p> <ul> <li>Drug Overview</li> <li>Mechanism of Action</li> <li>Regulatory Status</li> <li>Clinical Trial Results</li> <li>Drug Uptake and Market Performance<br />  </li> </ul> <p><strong>Late-Stage Pipeline Drugs</strong></p> <ul> <li>Drug Overview</li> <li>Mechanism of Action</li> <li>Regulatory Status</li> <li>Clinical Trial Results</li> <li>Drug Uptake and Market Performance<br />  </li> </ul> <table align="center" border="1" cellpadding="1" cellspacing="1" dir="ltr" style="width:100%"> <thead> <tr> <th scope="col" style="text-align:left; width:50%"><strong>Drugs</strong></th> <th scope="col" style="text-align:left"><strong>Company Name</strong></th> </tr> </thead> <tbody> <tr> <td>Zinplava (bezlotoxumab)</td> <td>Merck & Co</td> </tr> <tr> <td>Rebyota (fecal microbiota, live - jslm)</td> <td>Rebiotix</td> </tr> <tr> <td>Vowst (fecal microbiota spores, live-brpk)</td> <td>Seres Health</td> </tr> <tr> <td>Dificid (Fidaxomicin)</td> <td>Merck</td> </tr> <tr> <td>VE303</td> <td>Vedanta Biosciences</td> </tr> <tr> <td>RBX7455</td> <td>Rebiotix</td> </tr> <tr> <td>CP101</td> <td>Finch Research and Development</td> </tr> <tr> <td>MGB BP 3</td> <td>MGB Biopharma</td> </tr> <tr> <td>PF-06425090</td> <td>Pfizer</td> </tr> </tbody> </table> <p><br /> <strong>*</strong><strong>Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.</strong></p> <h4><br /> <strong>Key Questions Answered in this Report:</strong></h4> <p><strong>Market Insights</strong></p> <ul> <li>How has the Clostridium difficile infection market performed so far and how will it perform in the coming years?</li> <li>What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?</li> <li>What was the country-wise size of the Clostridium difficile infection market across the seven major markets in 2023 and what will it look like in 2034?</li> <li>What is the growth rate of the Clostridium difficile infection market across the seven major markets and what will be the expected growth over the next ten years?</li> <li>What are the key unmet needs in the market?<br />  </li> </ul> <p><strong>Epidemiology Insights</strong></p> <ul> <li>What is the number of prevalent cases (2018-2034) of Clostridium difficile infection across the seven major markets?</li> <li>What is the number of prevalent cases (2018-2034) of Clostridium difficile infection by age across the seven major markets?</li> <li>What is the number of prevalent cases (2018-2034) of Clostridium difficile infection by gender across the seven major markets?</li> <li>What is the number of prevalent cases (2018-2034) of Clostridium difficile infection by type across the seven major markets?</li> <li>How many patients are diagnosed (2018-2034) with Clostridium difficile infection across the seven major markets?</li> <li>What is the size of the Clostridium difficile infection patient pool (2018-2023) across the seven major markets?</li> <li>What would be the forecasted patient pool (2024-2034) across the seven major markets?</li> <li>What are the key factors driving the epidemiological trend of Clostridium difficile infection?</li> <li>What will be the growth rate of patients across the seven major markets?<br />  </li> </ul> <p><strong>Clostridium Difficile Infection: Current Treatment Scenario, Marketed Drugs and Emerging Therapies</strong></p> <ul> <li>What are the current marketed drugs and what are their market performance?</li> <li>What are the key pipeline drugs and how are they expected to perform in the coming years?</li> <li>How safe are the current marketed drugs and what are their efficacies?</li> <li>How safe are the late-stage pipeline drugs and what are their efficacies?</li> <li>What are the current treatment guidelines for Clostridium difficile infection drugs across the seven major markets?</li> <li>Who are the key companies in the market and what are their market shares?</li> <li>What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Clostridium difficile infection market?</li> <li>What are the key regulatory events related to the Clostridium difficile infection market?</li> <li>What is the structure of clinical trial landscape by status related to the Clostridium difficile infection market?</li> <li>What is the structure of clinical trial landscape by phase related to the Clostridium difficile infection market?</li> <li>What is the structure of clinical trial landscape by route of administration related to the Clostridium difficile infection market?</li> </ul>

<h4><strong>市场概览：</strong></h4> <blockquote> <p><em>截至2023年，7大主要艰难梭菌感染市场的总价值已达到90亿美元。</em>展望未来，IMARC集团预计7个主要市场将在2034年达到149亿美元，预计2024-2034年间的复合年增长率(CAGR)将为4.7%。</p> </blockquote> <table align="center" border="1" cellpadding="1" cellspacing="1" dir="ltr" style="width:100%"> <thead> <tr> <th scope="col" style="width:70%"> <div style="text-align:left">报告属性</div> </th> <th scope="col"> <div style="text-align:left">关键统计数据</div> </th> </tr> </thead> <tbody> <tr> <td><strong>基准年</strong></td> <td> <div>2023</div> </td> </tr> <tr> <td><strong>预测年</strong></td> <td>2024-2034</td> </tr> <tr> <td><strong>历史年</strong></td> <td> <div>2018-2023</div> </td> </tr> <tr> <td> <div><strong>2023年市场规模</strong></div> </td> <td>90亿美元</td> </tr> <tr> <td> <div><strong>2034年市场规模预测</strong></div> </td> <td>149亿美元</td> </tr> <tr> <td> <div><strong>2024-2034年市场增长率</strong></div> </td> <td>4.7%</td> </tr> </tbody> </table> <p style="text-align:justify"><br /> 在IMARC集团最新发布的报告《艰难梭菌感染市场：流行病学、行业趋势、份额、规模、增长、机遇及预测（2024-2034）》中，对艰难梭菌感染市场进行了全面的分析。艰难梭菌感染（CDI）是由致病菌艰难梭菌（Clostridium difficile，简称C. difficile）引起的细菌感染。该菌可以定植于结肠，破坏肠道正常菌群平衡，导致一系列胃肠道症状。CDI的症状严重程度各异，可能包括水样腹泻、腹痛、发热、食欲不振和恶心。在严重病例中，疾病可能进展为伪膜性结肠炎，这是一种更严重的结肠炎症，可能导致危及生命的并发症。CDI的诊断通常涉及多个步骤。主要方法是检测粪便样本中是否存在艰难梭菌毒素或细菌本身。阳性检测结果加上临床症状通常足以确诊感染。此外，医疗保健提供者可能会进行结肠镜检查或乙状结肠镜检查，以直观检查结肠炎症或伪膜。</p> <p style="text-align:center"><img alt="艰难梭菌感染市场" src="https://www.imarcgroup.com/CKEditor/80918a30-8b27-4ba5-bc3a-e8b643ffdee8clostridium-difficile-infection-market.webp" style="height:450px; width:800px" /></p> <p style="text-align:justify">由于广谱抗生素的使用增加，这些抗生素可能会破坏结肠中有益菌群的平衡，从而允许艰难梭菌过度生长并产生毒素导致感染，这是艰难梭菌感染市场增长的主要驱动力。除此之外，对有效药物（如万古霉素和替加环素）的需求不断上升，以及粪便微生物群移植（FMT）在恢复健康肠道微生物群方面的应用兴起，也为市场带来了积极的展望。此外，医疗机构中感染控制措施和严格的卫生程序的广泛应用，因为它们在预防CDI传播中发挥着至关重要的作用，进一步推动了市场增长。此外，快速诊断测试（如酶联免疫吸附试验（ELISA）和核酸扩增试验（NAAT））在早期和准确检测疾病方面的应用日益普及，这也是推动市场增长的重要因素。此外，针对细菌毒素的单克隆抗体等创新治疗方法的兴起，有助于中和细菌的有害作用，也在增强市场增长。此外，针对艰难梭菌的新型疫苗的研究正在进行中，旨在预防高风险人群的CDI发生，预计将在预测期间推动艰难梭菌感染市场的增长。</p> <p style="text-align:justify">IMARC集团的新报告对美国的艰难梭菌感染市场、欧盟4国（德国、西班牙、意大利和法国）、英国和日本的艰难梭菌感染市场进行了全面分析。这包括治疗实践、上市和研发药物、个别疗法的市场份额、七个主要市场的市场表现、关键公司的市场表现及其药物等。该报告还提供了七个主要市场的当前和未来患者群体。根据报告，美国拥有最大的艰难梭菌感染患者群体，也是其治疗市场最大的国家。此外，该报告还提供了当前的治疗实践/算法、市场驱动因素、挑战、机遇、报销情况、未满足的医疗需求等。本报告对于制造商、投资者、商业策略家、研究人员、顾问以及所有有意进入艰难梭菌感染市场的人来说都是必读之作。</p> <h4 style="text-align:justify"><strong>近期发展：</strong></h4> <ul> <li style="text-align:justify">2024年5月，Vedanta Biosciences报告称，全球第3期RESTORATiVE303临床试验的第一位患者已经接受给药。RESTORATiVE303试验正在评估VE303在复发性艰难梭菌感染患者中的有效性和安全性。该试验旨在为向美国食品药品监督管理局（FDA）提交的生物制品许可申请（BLA）奠定基础。</li> </ul> <h4 style="text-align:justify"><br /> <strong>关键要点：</strong></h4> <ul> <li style="text-align:justify">艰难梭菌引起15-25%的与抗生素相关的腹泻和几乎所有与抗生素相关的伪膜性结肠炎病例。</li> <li style="text-align:justify">超过90%的艰难梭菌感染发生在或在接受抗生素治疗期间。</li> <li style="text-align:justify">艰难梭菌的无症状携带者可以污染医院环境。携带者的频率在大约3%的健康人群中，在住院患者中为20-30%，在长期住院患者中为50%。</li> <li style="text-align:justify">美国疾病控制与预防中心（CDC）估计，艰难梭菌每年在美国导致近五十万例疾病。</li> <li style="text-align:justify">每11位65岁以上的患者中，就有1位在确诊医疗相关艰难梭菌感染后一个月内死亡。</li> </ul> <h4 style="text-align:justify"><br /> <strong>药物：</strong></h4> <p style="text-align:justify">ZINPLAVA是一种人源化单克隆抗体，可结合艰难梭菌毒素B。它用于降低接受抗生素治疗以治疗艰难梭菌感染（CDI）且复发风险较高的1岁及以上成人和儿科患者的CDI复发。</p> <p style="text-align:justify">VE303是一种潜在的首创新生生物治疗产品（LBP）候选药物，由特定的细菌群落组成，旨在预防复发性艰难梭菌感染。它由八个菌株组成，这些菌株是通过Vedanta的产品引擎理性选择的。VE303由纯、克隆的细菌细胞库制成，结果是一种均匀的粉末状药用产品，消除了依赖不同成分的捐赠者粪便的需要。</p> <p style="text-align:justify">CP101是一种正在调查的微生物组治疗方法，通过单次口服给药提供整个微生物群落，消除了对肠道准备的需求。CP101旨在通过恢复多样的微生物群落和被认为有助于建立抗定植能力的重要生理机制来预防复发性艰难梭菌感染。</p> <p><br /> <strong>研究时间范围</strong></p> <ul> <li>基准年：2023</li> <li>历史时期：2018-2023</li> <li>市场预测：2024-2034<br />  </li> </ul> <p><strong><strong>涵盖国家</strong></strong></p> <ul> <li>美国</li> <li>德国</li> <li>法国</li> <li>英国</li> <li>意大利</li> <li>西班牙</li> <li>日本<br />  </li> </ul> <p><strong>每个国家涵盖的分析</strong></p> <ul> <li>历史、当前和未来的流行病学情景</li> <li>历史、当前和未来的艰难梭菌感染市场规模表现</li> <li>市场中的各种治疗类别的历史、当前和未来表现</li> <li>艰难梭菌感染市场中各种药物的销售额</li> <li>市场中的报销情况</li> <li>上市和研发药物</li> </ul> <h4><br /> <strong>竞争格局：</strong></h4> <p>本报告还提供了对当前艰难梭菌感染上市药物和后期研发药物进行详细分析。</p> <p><strong>上市药物</strong></p> <ul> <li>药物概述</li> <li>作用机制</li> <li>监管状况</li> <li>临床试验结果</li> <li>药物采用和市场表现<br />  </li> </ul> <p><strong>后期研发药物</strong></p> <ul> <li>药物概述</li> <li>作用机制</li> <li>监管状况</li> <li>临床试验结果</li> <li>药物采用和市场表现<br />  </li> </ul> <table align="center" border="1" cellpadding="1" cellspacing="1" dir="ltr" style="width:100%"> <thead> <tr> <th scope="col" style="text-align:left; width:50%"><strong>药物</strong></th> <th scope="col" style="text-align:left"><strong>公司名称</strong></th> </tr> </thead> <tbody> <tr> <td>Zinplava (bezlotoxumab)</td> <td>Merck & Co</td> </tr> <tr> <td>Rebyota (粪便微生物群，活 - jslm)</td> <td>Rebiotix</td> </tr> <tr> <td>Vowst (粪便微生物群孢子，活-brpk)</td> <td>Seres Health</td> </tr> <tr> <td>Dificid (Fidaxomicin)</td> <td>Merck</td> </tr> <tr> <td>VE303</td> <td>Vedanta Biosciences</td> </tr> <tr> <td>RBX7455</td> <td>Rebiotix</td> </tr> <tr> <td>CP101</td> <td>Finch Research and Development</td> </tr> <tr> <td>MGB BP 3</td> <td>MGB Biopharma</td> </tr> <tr> <td>PF-06425090</td> <td>Pfizer</td> </tr> </tbody> </table> <p><br /> <strong>*</strong><strong>请注意，上表中的药物仅代表部分上市/研发药物，完整的列表已在报告中提供。</strong></p> <h4><br /> <strong>本报告回答的关键问题：</strong></h4> <p><strong>市场洞察</strong></p> <ul> <li>艰难梭菌感染市场迄今为止的表现如何？未来几年将如何表现？</li> <li>2023年各种治疗类别的市场份额是多少？预计到2034年将如何表现？</li> <li>2023年七个主要市场的国家层面市场规模是多少？2034年将是什么样子？</li> <li>七个主要市场的艰难梭菌感染市场增长率是多少？未来十年预计将增长多少？</li> <li>市场中的关键未满足需求是什么？<br />  </li> </ul> <p><strong>流行病学洞察</strong></p> <ul> <li>七个主要市场艰难梭菌感染的患病人数（2018-2034）是多少？</li> <li>七个主要市场按年龄划分的艰难梭菌感染患病人数（2018-2034）是多少？</li> <li>七个主要市场按性别划分的艰难梭菌感染患病人数（2018-2034）是多少？</li> <li>七个主要市场按类型划分的艰难梭菌感染患病人数（2018-2034）是多少？</li> <li>七个主要市场有多少患者被诊断为艰难梭菌感染（2018-2034）？</li> <li>七个主要市场的艰难梭菌感染患者群体规模（2018-2023）是多少？</li> <li>七个主要市场的预测患者群体（2024-2034）将是什么样子？</li> <li>推动艰难梭菌感染流行病学趋势的关键因素是什么？</li> <li>七个主要市场的患者增长率将如何？<br />  </li> </ul> <p><strong>艰难梭菌感染：当前治疗情景、上市药物和新兴疗法</strong></p> <ul> <li>当前上市药物是什么？它们的销售情况如何？</li> <li>关键研发药物是什么？预计在未来几年将如何表现？</li> <li>当前上市药物的安全性如何？它们的疗效如何？</li> <li>后期研发药物的安全性如何？它们的疗效如何？</li> <li>七个主要市场的艰难梭菌感染药物的当前治疗指南是什么？</li> <li>市场中的关键公司是谁？它们的市场份额是多少？</li> <li>与艰难梭菌感染市场相关的关键并购、许可活动、合作等是什么？</li> <li>与艰难梭菌感染市场相关的关键监管事件是什么？</li> <li>与艰难梭菌感染市场相关的临床试验景观的结构（按状态）是什么？</li> <li>与艰难梭菌感染市场相关的临床试验景观的结构（按阶段）是什么？</li> <li>与艰难梭菌感染市场相关的临床试验景观的结构（按给药途径）是什么？</li> </ul>

提供机构：